Insider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) CFO Sells 77,000 Shares of Stock

April 18, 2026 by InsiderTrades.com

Key Points

CFO Scott Giacobello sold 141,600 shares at an average of $4.13 on April 16 for about $584,808 to cover tax withholding on vested awards, reducing his stake by 32.42% to 295,224 shares; additional insider sales this week likely increased selling pressure.
Stock and analyst backdrop: WHWK opened at $4.11 (52‑week range $1.39–$4.48) with a market cap near $194M, and mixed analyst coverage — a consensus "Moderate Buy" with an average $7 price target but divergent ratings.
Recent results and catalysts: The company beat quarterly EPS estimates (‑$0.34 vs. ‑$0.55 expected) and faces upcoming visibility events and trial data that analysts view as potential near‑term catalysts.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CFO Scott Giacobello sold 77,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $3.86, for a total transaction of $297,220.00. Following the completion of the transaction, the chief financial officer owned 436,824 shares of the company's stock, valued at approximately $1,686,140.64. The trade was a 14.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Whitehawk Therapeutics Price Performance

WHWK stock opened at $4.11 on Friday. The firm has a market capitalization of $193.99 million, a P/E ratio of 8.74 and a beta of 0.57. Whitehawk Therapeutics, Inc. has a 52-week low of $1.39 and a 52-week high of $4.48. The company's 50 day simple moving average is $3.46 and its 200-day simple moving average is $2.78.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.21.

Key Headlines Impacting Whitehawk Therapeutics

Here are the key news stories impacting Whitehawk Therapeutics this week:

Positive Sentiment: Citizens/JMP initiated coverage with a "Market Outperform" and an $8.00 price target (roughly ~95% above recent levels), a catalyst that has supported buying interest ahead of impending trial data. Citizens Outperform
Neutral Sentiment: Whitehawk’s CEO will appear in a Jones Trading Post–AACR virtual fireside chat on April 23 — a visibility event that can help inform investors but is unlikely to move the stock by itself. Fireside Chat
Neutral Sentiment: Institutional ownership is meaningful (~52%) and coverage is mixed: a consensus "Hold" with an average target near $6.50 (some firms bullish, others negative), so analyst views are a mixed influence on price. Institutional Holdings
Negative Sentiment: Significant insider selling this week — CFO Scott Giacobello sold 141,600 shares (4/16) and 77,000 shares (4/15) and director/officer Bryan Ball sold multiple blocks — has increased supply and likely pressured the stock. Company disclosures say the sales were to cover tax withholding on vested awards, but the size and frequency of sales reduced insiders' stakes materially. SEC filings: CFO Form 4 and Other Insider Forms

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. KVP Capital Advisors LP bought a new position in shares of Whitehawk Therapeutics during the 4th quarter valued at $5,242,000. Quadrature Capital Ltd bought a new position in Whitehawk Therapeutics during the fourth quarter valued at about $28,000. Eversept Partners LP acquired a new stake in shares of Whitehawk Therapeutics in the fourth quarter worth about $630,000. ADAR1 Capital Management LLC bought a new stake in shares of Whitehawk Therapeutics during the 4th quarter worth about $188,000. Finally, Marshall Wace LLP acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter valued at about $164,000. Institutional investors and hedge funds own 52.08% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wall Street Zen lowered Whitehawk Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, April 11th. Oppenheimer assumed coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an "outperform" rating and a $6.00 price objective on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. JonesTrading assumed coverage on shares of Whitehawk Therapeutics in a research note on Monday, December 22nd. They set a "buy" rating and a $7.00 target price for the company. Finally, Citigroup assumed coverage on shares of Whitehawk Therapeutics in a report on Thursday. They set an "outperform" rating on the stock. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $7.00.

Read Our Latest Analysis on Whitehawk Therapeutics

Whitehawk Therapeutics Company Profile

(Get Free Report)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.